{"entity":{"id":"clio-8421","kind":"drug","name":"CLIO-8421","aka":[],"tldr":"CLIO-8421 is an experimental dual-payload antibody-drug conjugate from Callio Therapeutics, in preclinical development for non-small cell lung cancer and metastatic breast cancer.","summary":"CLIO-8421 is a dual-payload antibody-drug conjugate from Callio Therapeutics. A TROP2-directed dual-payload ADC; the company names only the target. Its furthest stage is preclinical development, for non-small cell lung cancer and metastatic breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling on the company pipeline chart. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Callio Therapeutics: calliotx.com","url":"https://calliotx.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":["callio-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CLIO-8421","modality":"Dual-payload antibody-drug conjugate","mechanism":"A TROP2-directed dual-payload ADC; the company names only the target.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/clio-8421/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/"}]}}